Streetbeat News

Products Services

AAPL

GOOGL

MSFT

Apple Inc. is in discussions with both Alphabet Inc.'s Google and Microsoft Corp.-backed OpenAI to potentially integrate their large-language AI models into the iPhone's AI features, aiming to enhance Siri and other on-device capabilities. No decision has been made yet, and any formal announcement is not expected until the summer. The talks are part of Apple's broader strategy to advance its AI capabilities, with iOS 18 playing a significant role. Analysts see a potential partnership, especially with Google, as a win-win, potentially benefiting Google through substantial annual payments and distribution across Apple's vast device ecosystem.

Portfolio Pulse from Rounak Jain

March 21, 2024 | 1:56 pm

ASST

INTJ

KAVL

MVLA

TRML

YTEN

U.S. stocks traded higher with the Dow Jones gaining around 200 points. Information technology shares rose by 0.9%, while consumer staples fell by 0.1%. U.S. initial jobless claims declined to 210,000. Yield10 Bioscience, Kaival Brands Innovations Group, and Asset Entities saw significant stock movements after specific company announcements. Movella Holdings, Tourmaline Bio, and Intelligent Group Limited experienced notable declines.

Portfolio Pulse from Avi Kapoor

March 21, 2024 | 1:47 pm

BNOX

Bionomics Limited (NASDAQ:BNOX) released detailed data from its Phase 2b ATTUNE trial of BNC210 for PTSD, showing significant improvements in primary and several secondary endpoints. The trial demonstrated BNC210's efficacy in reducing PTSD symptoms, depressive symptoms, and improving sleep, with a favorable safety profile. Bionomics plans to discuss these results with the FDA in Q2 2024 and proceed to a late-stage trial in Q4 2024. Following the news, BNOX shares experienced volatility, dropping 1.09% to $1.03 after initially spiking to $1.30 in premarket trading.

Portfolio Pulse from Vandana Singh

March 21, 2024 | 1:36 pm

LUCD

PAVM

Lucid Diagnostics Inc. (LUCD) and its majority-owned parent company PAVmed Inc. (PAVM) announced positive results from the first prospective clinical validation study of EsoGuard, a test for esophageal precancer detection. Conducted at the Louis Stokes Cleveland Veterans Affairs Medical Center, the study showed EsoGuard's sensitivity at 92.9% and negative predictive value at 98.6%. These results, along with previous studies, support EsoGuard's use as a screening tool for esophageal precancer and cancer, potentially leading to broader medical policy coverage and CMS coverage.

Portfolio Pulse from Benzinga Newsdesk

March 21, 2024 | 1:31 pm

BZUN

PGJ

Baozun Inc (NASDAQ: BZUN) reported Q4 fiscal 2023 revenue of $391.6 million, up 8.9% Y/Y, beating consensus of $382.2 million but missed EPS estimates with $0.07 vs. $0.16 expected. The stock dropped 8.33% in premarket trading. Revenue growth was driven by its new Baozun Brand Management line. Product sales revenue increased by 36.3%, while services revenue decreased by 3.0%. The adjusted operating margin fell to 2.7% from 7.2% a year ago. Baozun's stock has lost 50% of its value over the past year. Baozun is also part of the Invesco Golden Dragon China ETF (NASDAQ: PGJ).

Portfolio Pulse from Anusuya Lahiri

March 21, 2024 | 1:27 pm

BRK

DKNG

MGM

PARA

PEP

WBD

The 2024 NCAA Men's Basketball Tournament highlights the incredibly low odds of achieving a perfect bracket, with Connecticut as the favorite. DraftKings, BetMGM, Bally's Corp, Berkshire Hathaway, and PepsiCo are engaging fans with contests and promotions, while Warner Bros. Discovery and Paramount Global hold broadcasting rights. The odds of a perfect bracket are 1 in 9.2 quintillion, but knowledge of basketball improves odds to 1 in 128 billion.

Portfolio Pulse from Chris Katje

March 21, 2024 | 1:20 pm

ARGX

Argenx shares are trading higher due to disappointing myasthenia gravis data from competitors Chugai and Roche, indicating a competitive advantage for Argenx.

Portfolio Pulse from Benzinga Newsdesk

March 21, 2024 | 1:12 pm

BMY

The European Commission approved Bristol Myers Squibb's Abecma for early treatment of relapsed and refractory multiple myeloma, marking it as the first CAR-T therapy for this condition in the EU. Additionally, the company announced positive results from a trial of Opdivo plus Yervoy for advanced hepatocellular carcinoma, showing significant improvement in overall survival. BMY shares rose 0.29% in premarket trading.

Portfolio Pulse from Vandana Singh

March 21, 2024 | 1:10 pm

WILC

G. Willi-Food International Ltd. (NASDAQ:WILC) reported a 9% increase in sales for fiscal year 2023, reaching a record high despite a decrease in gross and operating profit. The company faced challenges such as the appreciation of the Israeli shekel, worldwide increase in goods prices, and increased transport costs due to military conflicts. Despite these, Willi-Food expanded its product range and improved product visibility, and is working on improving commercial terms and constructing a new logistics center to support growth.

Portfolio Pulse from Benzinga Newsdesk

March 21, 2024 | 1:08 pm

CHH

Choice Privileges has introduced a new auction tool, expanding its offerings with new experiences in sports and music through partnerships with Learfield and Monumental Sports & Entertainment. Members can now bid on these experiences.

Portfolio Pulse from Benzinga Newsdesk

March 21, 2024 | 1:07 pm